Top 5 Stocks to Buy Now
→ Millionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon. (From Brownstone Research) (Ad)tc pixel Free CRMD Stock Alerts

CorMedix (CRMD) Financials

CorMedix logo
$7.85 +0.13 (+1.68%)
Closing price 04:00 PM Eastern
Extended Trading
$7.81 -0.04 (-0.51%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for CorMedix

Annual Income Statements for CorMedix

This table shows CorMedix's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -18 -25 -33 -27 -44 -22 -28 -30 -46 -18 163
Consolidated Net Income / (Loss)		 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18 163
Net Income / (Loss) Continuing Operations		 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18 163
Total Pre-Tax Income 		-18 -25 -33 -27 -21 -27 -29 -30 -46 -19 150
Total Operating Income		 -17 -25 -33 -27 -21 -27 -29 -31 -49 -22 150
Total Gross Profit		 -0.11 -0.14 0.21 0.03 -0.09 0.03 0.04 0.06 0.00 40 276
Total Revenue		 0.21 0.22 0.33 0.43 0.28 0.24 0.19 0.07 0.00 43 298
Operating Revenue		 0.21 0.22 0.33 0.43 0.28 0.24 0.19 0.07 0.00 43 298
Total Cost of Revenue		 -0.32 0.37 0.11 0.40 0.37 0.20 0.15 0.00 0.00 3.03 22
Operating Cost of Revenue		 0.32 0.37 0.11 0.40 0.37 0.20 0.15 0.00 0.00 3.03 22
Total Operating Expenses		 17 25 33 27 21 27 29 31 49 63 126
Selling, General & Admin Expense		 10 8.88 8.65 8.07 9.87 14 16 20 18 30 68
Marketing Expense		 - - - - - - - - 18 29 38
Research & Development Expense		 6.28 16 24 19 11 13 13 11 13 3.94 19
Total Other Income / (Expense), net		 -1.53 0.12 -0.17 0.03 -0.49 0.11 -0.02 0.34 2.62 3.03 -0.13
Interest Expense		 0.00 0.00 0.01 0.00 0.79 0.03 0.02 0.03 0.03 0.04 2.78
Interest & Investment Income		 0.06 0.13 0.11 0.03 0.32 0.12 0.01 0.33 2.68 2.58 3.85
Other Income / (Expense), net		 -1.59 -0.01 -0.28 -0.00 -0.02 0.02 -0.02 0.04 -0.03 0.49 -1.19
Income Tax Expense		 - - - 0.00 -5.06 -5.17 -1.25 -0.59 0.00 -1.40 -13
Basic Earnings per Share		 ($0.58) ($0.65) ($0.60) ($1.51) ($1.80) ($0.77) ($0.75) ($0.74) ($0.91) ($0.30) $2.25
Weighted Average Basic Shares Outstanding		 31.34M 37.97M 55.14M 17.82M 24.15M 28.56M 37.67M 40.27M 50.90M 58.87M 72.03M
Diluted Earnings per Share		 ($0.58) ($0.65) ($0.60) ($1.51) ($1.80) ($0.77) - - ($0.91) ($0.30) $2.04
Weighted Average Diluted Shares Outstanding		 31.34M 37.97M 55.14M 17.82M 24.15M 28.56M 37.67M 44.50M 50.90M 58.87M 80.31M
Weighted Average Basic & Diluted Shares Outstanding		 31.34M 37.97M 55.14M 17.82M 24.15M 28.56M 37.67M 44.50M 54.98M - 79.05M

Quarterly Income Statements for CorMedix

This table shows CorMedix's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -9.75 -15 -14 -14 -2.78 13 21 20 109 14 39
Consolidated Net Income / (Loss)		 -9.74 -15 -14 -14 -2.78 13 21 20 109 14 39
Net Income / (Loss) Continuing Operations		 -9.74 -15 -14 -14 -2.78 13 21 20 109 14 39
Total Pre-Tax Income 		-9.74 -15 -16 -14 -2.78 13 21 20 53 56 56
Total Operating Income		 -10 -16 -17 -15 -3.29 13 20 20 51 59 64
Total Gross Profit		 0.00 - -0.82 0.30 11 30 37 38 93 107 105
Total Revenue		 0.00 - 0.00 0.81 11 31 39 40 101 118 127
Operating Revenue		 0.00 - 0.00 0.81 11 31 39 40 101 118 127
Total Cost of Revenue		 0.00 - 0.82 0.51 0.63 1.18 1.60 1.86 7.57 11 22
Operating Cost of Revenue		 0.00 - 0.82 0.51 0.63 1.18 1.60 1.86 7.57 11 22
Total Operating Expenses		 10 16 16 16 14 17 17 18 42 48 41
Selling, General & Admin Expense		 3.74 2.58 8.71 7.56 6.58 0.77 9.69 9.50 25 24 22
Marketing Expense		 4.06 - 6.34 7.39 6.75 - 4.47 6.38 11 16 13
Research & Development Expense		 2.66 2.29 0.84 0.65 0.73 1.73 3.19 2.44 5.10 8.60 7.21
Total Other Income / (Expense), net		 0.72 0.91 0.84 1.15 0.51 1.03 0.52 0.81 1.23 -2.68 -8.01
Other Income / (Expense), net		 -0.03 0.00 -0.00 0.50 -0.03 0.53 0.52 -0.02 0.62 -1.75 -8.01
Income Tax Expense		 0.00 - -1.39 0.00 0.00 - 0.00 0.52 -56 42 17
Basic Earnings per Share		 ($0.17) ($0.25) ($0.25) ($0.25) ($0.05) $0.25 $0.32 $0.29 $1.42 $0.22 $0.48
Weighted Average Basic Shares Outstanding		 56.55M 50.90M 57.50M 57.62M 58.83M 58.87M 65.24M 67.93M 75.93M 72.03M 79.51M
Diluted Earnings per Share		 ($0.17) - ($0.25) ($0.25) ($0.05) - $0.30 $0.28 $1.26 $0.20 $0.43
Weighted Average Diluted Shares Outstanding		 56.55M 50.90M 57.50M 57.62M 58.83M 58.87M 68.98M 71.92M 86.21M 80.31M 92.99M
Weighted Average Basic & Diluted Shares Outstanding		 54.81M 54.98M 54.96M 55.86M 60.68M 0.00 67.82M 74.65M 78.79M 79.05M 78.45M

Annual Cash Flow Statements for CorMedix

This table details how cash moves in and out of CorMedix's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 7.48 -3.75 2.32 7.24 -1.27 26 11 -10 0.45 -3.07 105
Net Cash From Operating Activities		 -13 -22 -29 -24 -15 -22 -21 -24 -38 -51 175
Net Cash From Continuing Operating Activities		 -13 -22 -29 -24 -15 -22 -21 -24 -38 -51 175
Net Income / (Loss) Continuing Operations		 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18 163
Consolidated Net Income / (Loss)		 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18 163
Depreciation Expense		 0.02 0.03 0.04 0.07 0.07 0.13 0.06 0.08 0.07 0.15 0.68
Amortization Expense		 - - 0.00 0.00 0.31 0.03 0.12 0.12 0.13 0.30 15
Non-Cash Adjustments To Reconcile Net Income		 5.64 2.59 1.51 1.11 2.54 0.66 5.05 4.07 5.49 6.27 8.63
Changes in Operating Assets and Liabilities, net		 0.01 -0.23 2.88 1.94 -1.54 -0.76 1.84 1.07 2.23 -39 -12
Net Cash From Investing Activities		 -24 11 10 1.56 -12 7.43 -9.13 -3.71 -17 21 -308
Net Cash From Continuing Investing Activities		 -24 11 10 1.56 -12 7.43 -9.13 -3.71 -17 21 -308
Purchase of Property, Plant & Equipment		 -0.02 -0.06 -0.15 -0.05 -0.04 -0.11 -1.43 -0.22 -0.33 -0.12 -2.26
Acquisitions		 - - - - - - - - - 0.00 -309
Purchase of Investments		 -24 0.00 -13 0.00 -14 -8.55 - -31 -77 -27 -53
Sale and/or Maturity of Investments		 - 11 24 1.60 2.12 16 -7.71 28 60 48 55
Net Cash From Financing Activities		 44 7.09 21 29 26 40 42 18 56 26 238
Net Cash From Continuing Financing Activities		 44 7.09 21 30 26 40 42 18 56 26 238
Repayment of Debt		 0.00 - - 0.00 - - - - - 0.00 -0.19
Repurchase of Common Equity		 - - - - -0.23 - - - - 0.00 -5.73
Issuance of Debt		 - - 0.00 7.50 2.00 - - - - 0.00 150
Issuance of Common Equity		 28 6.23 19 22 15 40 41 18 56 19 90
Other Financing Activities, net		 15 0.86 0.01 0.04 8.80 0.41 0.30 0.13 0.09 7.44 4.21
Effect of Exchange Rate Changes		 -0.02 0.00 0.02 -0.01 -0.00 0.01 -0.01 -0.01 0.00 -0.00 0.00
Cash Interest Paid		 0.00 0.00 0.01 0.00 0.01 0.03 0.02 0.03 0.03 0.04 0.02

Quarterly Cash Flow Statements for CorMedix

This table details how cash moves in and out of CorMedix's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 34 -9.68 -8.46 -6.71 6.75 5.36 26 93 -110 96 33
Net Cash From Operating Activities		 -8.70 -11 -17 -14 -14 -5.61 20 30 31 94 42
Net Cash From Continuing Operating Activities		 -8.70 -11 -17 -14 -14 -5.75 20 30 31 95 43
Net Income / (Loss) Continuing Operations		 -9.74 -15 -14 -14 -2.78 13 21 20 109 14 39
Consolidated Net Income / (Loss)		 -9.74 -15 -14 -14 -2.78 13 21 20 109 14 39
Depreciation Expense		 0.02 0.02 0.02 0.02 0.03 0.08 0.16 0.11 0.16 0.29 11
Non-Cash Adjustments To Reconcile Net Income		 1.00 1.22 2.44 1.26 1.23 1.19 3.55 2.68 1.20 1.26 8.85
Changes in Operating Assets and Liabilities, net		 -0.01 2.74 -5.35 -1.27 -12 -21 -4.62 7.29 -83 68 -15
Net Cash From Investing Activities		 -0.59 0.60 8.94 6.27 6.32 -0.30 -0.20 -20 -291 3.30 2.97
Net Cash From Continuing Investing Activities		 -0.59 0.60 8.94 6.27 6.32 -0.30 -0.20 -20 -291 3.30 2.97
Purchase of Property, Plant & Equipment		 -0.01 -0.30 -0.06 -0.03 -0.01 -0.01 -0.01 -0.02 -0.51 -1.72 -0.73
Purchase of Investments		 -18 -16 -7.69 -12 -1.67 -5.29 -9.99 -28 -15 -0.07 0.00
Sale and/or Maturity of Investments		 18 17 17 18 8.00 5.00 9.80 8.10 34 3.60 3.69
Net Cash From Financing Activities		 43 0.47 -0.10 1.06 14 11 6.09 83 151 -1.41 -12
Net Cash From Continuing Financing Activities		 43 0.47 -0.10 1.06 14 11 6.09 83 151 -1.41 -12
Repayment of Debt		 - - - - - - 0.00 - - -0.14 -0.14
Repurchase of Common Equity		 - - - - - - 0.00 - - -5.45 -11
Issuance of Common Equity		 43 0.43 0.00 - 12 5.51 6.76 82 0.00 1.03 0.00
Other Financing Activities, net		 0.02 0.03 -0.10 0.05 1.71 5.78 -0.67 0.88 0.86 3.15 -0.87
Effect of Exchange Rate Changes		 -0.00 0.00 -0.00 -0.00 0.00 -0.00 0.00 0.00 - - 0.00
Cash Interest Paid		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 - 0.00 2.82

Annual Balance Sheets for CorMedix

This table presents CorMedix's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 37 22 13 19 29 49 69 62 82 119 826
Total Current Assets		 37 22 13 19 29 48 66 60 79 115 367
Cash & Equivalents		 12 8.06 10 18 16 42 53 43 44 41 145
Short-Term Investments		 24 12 1.60 0.00 12 4.44 12 16 32 11 3.69
Accounts Receivable		 0.32 0.01 0.06 0.01 0.00 0.00 0.05 - 0.00 52 171
Inventories, net		 0.38 0.17 0.59 0.43 0.34 0.14 0.00 0.00 2.11 7.60 30
Prepaid Expenses		 0.81 1.32 0.45 0.43 0.48 1.47 0.82 0.63 1.24 3.63 18
Plant, Property, & Equipment, net		 0.04 0.07 0.19 0.16 0.12 0.11 1.47 1.61 1.87 1.83 5.96
Total Noncurrent Assets		 0.01 0.01 0.00 0.00 0.00 1.01 1.00 0.88 0.74 2.44 453
Long-Term Investments		 - - - - - - 0.10 0.10 0.10 0.11 28
Goodwill		 - - - - - - - - - 0.00 30
Intangible Assets		 - - - - - - - - 0.00 1.84 379
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - - 0.00 16
Total Liabilities & Shareholders' Equity		 37 22 13 19 29 49 69 62 82 119 826
Total Liabilities		 3.09 4.09 6.26 14 5.83 5.09 6.15 6.98 12 34 421
Total Current Liabilities		 3.06 4.09 6.26 7.77 5.83 4.16 5.35 6.31 11 34 174
Accounts Payable		 1.71 1.65 1.81 2.59 1.02 1.13 2.21 2.20 4.28 1.72 7.88
Accrued Expenses		 1.22 2.34 4.36 5.17 4.80 2.92 3.01 3.97 6.97 32 163
Other Current Liabilities		 - - - - 0.00 0.11 0.12 0.13 0.15 0.17 3.02
Total Noncurrent Liabilities		 0.03 0.00 0.00 6.13 0.00 0.92 0.80 0.67 0.52 0.35 247
Long-Term Debt		 - - 0.00 6.13 - - - - - 0.00 145
Other Noncurrent Operating Liabilities		 - - - 0.00 0.00 0.92 0.80 0.67 0.52 0.35 102
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 34 18 7.19 4.93 24 44 63 55 70 85 405
Total Preferred & Common Equity		 34 18 7.19 4.93 24 44 63 55 70 85 405
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 34 18 7.19 4.93 24 44 63 55 70 85 405
Common Stock		 128 137 159 184 219 262 308 330 392 424 582
Retained Earnings		 -94 -119 -152 -179 -195 -217 -246 -275 -322 -340 -177
Accumulated Other Comprehensive Income / (Loss)		 0.06 0.08 0.10 0.10 0.10 0.10 0.09 0.08 0.09 0.09 0.00

Quarterly Balance Sheets for CorMedix

This table presents CorMedix's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 62 59 57 91 68 58 78 150 253 751 816
Total Current Assets		 60 57 55 89 63 53 73 145 248 260 383
Cash & Equivalents		 43 25 20 53 35 29 35 66 159 48 178
Short-Term Investments		 16 30 33 33 23 17 11 11 31 7.22 0.00
Accounts Receivable		 0.00 - - - - 0.21 17 55 43 159 155
Inventories, net		 0.00 - - - 2.32 4.01 6.65 7.49 9.63 29 31
Prepaid Expenses		 0.55 1.05 2.14 2.39 2.46 3.37 3.09 5.26 4.80 16 19
Plant, Property, & Equipment, net		 1.50 1.61 1.60 1.59 1.91 1.92 1.90 1.73 1.64 7.52 6.17
Total Noncurrent Assets		 0.91 0.84 0.81 0.78 2.71 2.62 2.53 2.99 2.90 484 426
Long-Term Investments		 0.10 0.10 0.10 0.10 0.10 0.10 0.11 0.11 0.11 23 24
Goodwill		 - - - - - - - - - 18 30
Intangible Assets		 - - - - 2.00 1.95 1.90 1.79 1.74 390 369
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - - 53 3.31
Total Liabilities & Shareholders' Equity		 62 59 57 91 68 58 78 150 253 751 816
Total Liabilities		 5.76 5.31 7.98 8.23 10 12 19 35 32 377 379
Total Current Liabilities		 5.06 4.67 7.39 7.67 9.53 11 18 34 32 134 129
Accounts Payable		 1.77 1.45 2.90 2.39 2.83 3.34 1.34 1.93 5.82 20 13
Accrued Expenses		 3.16 3.09 4.34 5.14 6.55 7.61 17 32 26 109 113
Other Current Liabilities		 0.13 0.14 0.14 0.15 0.15 0.16 0.16 0.17 0.18 3.25 3.18
Total Noncurrent Liabilities		 0.70 0.63 0.59 0.56 0.48 0.44 0.39 0.30 0.26 243 247
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - 145 145
Other Noncurrent Operating Liabilities		 - 0.63 - - - 0.44 0.39 0.30 0.26 96 102
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 56 54 49 83 58 46 59 115 221 374 437
Total Preferred & Common Equity		 56 54 49 83 58 46 59 115 221 374 437
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 56 54 49 83 58 46 59 115 221 374 437
Common Stock		 323 340 346 390 394 396 412 434 520 565 575
Retained Earnings		 -267 -286 -297 -307 -336 -350 -353 -319 -299 -191 -138
Accumulated Other Comprehensive Income / (Loss)		 0.05 0.10 0.09 0.08 0.08 0.09 0.09 0.08 0.08 0.09 0.00

Annual Metrics And Ratios for CorMedix

This table displays calculated financial ratios and metrics derived from CorMedix's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 54,812,042.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 54,812,042.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 2.97
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 11.02% 6.65% 46.95% 30.51% -34.09% -15.55% -20.19% -65.74% -100.00% 0.00% 585.12%
EBITDA Growth		 -1.91% -35.74% -34.03% 19.22% 22.95% -30.97% -8.31% -3.74% -60.58% 56.11% 867.57%
EBIT Growth		 -1.91% -35.77% -34.04% 19.09% 21.72% -29.33% -8.32% -3.83% -60.16% 55.36% 781.14%
NOPAT Growth		 -87.08% -48.68% -32.97% 18.41% 21.80% -29.57% -8.14% -4.03% -59.87% 54.34% 1,142.81%
Net Income Growth		 11.08% -35.50% -33.95% 18.72% 38.75% -34.04% -28.07% -5.29% -56.02% 61.31% 1,009.40%
EPS Growth		 39.58% -12.07% -33.95% 18.72% -19.21% 57.22% 0.00% 0.00% 0.00% 67.03% 780.00%
Operating Cash Flow Growth		 -98.18% -77.74% -28.39% 17.09% 36.49% -45.94% 3.70% -15.13% -57.70% -31.78% 445.84%
Free Cash Flow Firm Growth		 10.77% -51.21% -25.99% 17.35% 2.66% -30.29% 7.30% -1.79% -57.81% -69.72% -225.32%
Invested Capital Growth		 -119.25% -63.17% -96.72% -35.74% 27.80% 52.34% -25.21% -36.42% -53.29% 641.51% 1,036.87%
Revenue Q/Q Growth		 -12.07% 41.43% -8.14% -13.31% -0.61% 0.00% 0.00% -28.98% -100.00% 240.63% 41.37%
EBITDA Q/Q Growth		 -10.00% -12.26% -13.10% 31.67% -57.50% -2.01% -6.27% -2.16% -17.41% 57.74% 51.00%
EBIT Q/Q Growth		 -9.99% -12.27% -13.09% 31.60% -55.84% -2.38% -6.44% -2.16% -17.33% 57.12% 42.48%
NOPAT Q/Q Growth		 -11.21% -11.98% -12.77% 31.60% -55.69% -2.67% -6.11% -2.03% -17.47% 56.13% 3.40%
Net Income Q/Q Growth		 -9.99% -12.03% -13.00% 31.71% -82.99% -3.68% -6.43% -1.43% -16.45% 61.15% 0.34%
EPS Q/Q Growth		 -87.10% -14.04% -13.00% 31.71% -19.21% 0.00% 0.00% 0.00% 0.00% 0.00% -2.39%
Operating Cash Flow Q/Q Growth		 -19.69% -14.76% -2.80% 0.32% 18.05% -10.29% 0.30% -1.19% -13.57% 9.20% 133.49%
Free Cash Flow Firm Q/Q Growth		 -17.66% -16.30% 1.77% -22.69% 23.45% -9.60% -3.14% 5.51% -13.40% -6.47% -37.74%
Invested Capital Q/Q Growth		 5.25% 17.18% -98.16% 58.20% -24.64% 15.81% -5.16% -79.85% -101.22% 161.29% 24.83%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -51.68% -63.62% 65.09% 7.68% -31.76% 14.37% 22.00% 94.29% 0.00% 92.66% 92.58%
EBITDA Margin		 -8,675.05% -11,041.03% -10,070.21% -6,233.21% -7,287.37% -11,300.69% -15,335.95% -46,443.53% 0.00% -49.25% 55.18%
Operating Margin		 -7,925.56% -11,048.80% -9,997.39% -6,250.44% -7,416.31% -11,378.44% -15,417.51% -46,819.91% 0.00% -51.43% 50.41%
EBIT Margin		 -8,682.22% -11,052.45% -10,081.41% -6,250.48% -7,423.78% -11,368.54% -15,428.66% -46,763.12% 0.00% -50.30% 50.01%
Profit (Net Income) Margin		 -8,655.37% -10,996.46% -10,023.45% -6,242.40% -5,801.29% -9,207.70% -14,774.70% -45,409.90% 0.00% -41.24% 54.75%
Tax Burden Percent		 103.63% 100.00% 99.74% 100.00% 76.45% 80.99% 95.76% 98.07% 100.00% 92.78% 108.69%
Interest Burden Percent		 96.20% 99.49% 99.68% 99.87% 102.21% 100.00% 100.01% 99.02% 94.60% 88.37% 100.71%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.69%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -116.81% 80.29%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -113.25% 80.62%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 93.64% -13.74%
Return on Equity (ROE)		 -96.62% -95.10% -264.00% -442.46% -114.99% -64.91% -52.72% -50.40% -74.02% -23.17% 66.56%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -166.09% -87.37%
Operating Return on Assets (OROA)		 -86.47% -83.95% -187.79% -166.45% -87.07% -69.04% -49.82% -46.70% 0.00% -21.77% 31.52%
Return on Assets (ROA)		 -86.20% -83.53% -186.71% -166.23% -68.04% -55.92% -47.71% -45.35% 0.00% -17.85% 34.51%
Return on Common Equity (ROCE)		 -96.62% -95.10% -263.99% -442.42% -114.99% -64.91% -52.72% -50.40% -74.02% -23.17% 66.56%
Return on Equity Simple (ROE_SIMPLE)		 -53.47% -138.33% -458.89% -543.74% -69.50% -49.81% -44.92% -53.94% -66.06% -21.18% 0.00%
Net Operating Profit after Tax (NOPAT)		 -12 -17 -23 -19 -15 -19 -21 -21 -34 -16 163
NOPAT Margin		 -5,547.89% -7,734.16% -6,998.17% -4,375.31% -5,191.41% -7,964.91% -10,792.26% -32,773.94% 0.00% -36.00% 54.79%
Net Nonoperating Expense Percent (NNEP)		 -32.73% -26.16% -61.33% -67.36% -8.60% -7.92% -13.55% -13.25% -17.85% -3.56% -0.33%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -48.86% -18.49% 29.67%
Cost of Revenue to Revenue		 -151.68% 163.62% 34.91% 92.32% 131.76% 85.63% 78.00% 5.71% 0.00% 7.34% 7.42%
SG&A Expenses to Revenue		 4,884.39% 3,963.79% 2,627.28% 1,878.73% 3,482.59% 5,801.06% 8,561.30% 30,586.61% 0.00% 68.92% 22.91%
R&D to Revenue		 2,989.49% 7,021.40% 7,435.20% 4,379.39% 3,901.95% 5,591.75% 6,878.21% 16,327.59% 0.00% 9.07% 6.49%
Operating Expenses to Revenue		 7,873.88% 10,985.19% 10,062.48% 6,258.12% 7,384.55% 11,392.81% 15,439.51% 46,914.20% 0.00% 144.09% 42.17%
Earnings before Interest and Taxes (EBIT)		 -18 -25 -33 -27 -21 -27 -29 -31 -49 -22 149
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -25 -33 -27 -21 -27 -29 -30 -49 -21 164
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.87 3.26 19.24 23.29 7.44 4.80 2.73 3.41 2.73 5.63 2.30
Price to Tangible Book Value (P/TBV)		 1.87 3.26 19.24 23.29 7.44 4.80 2.73 3.41 2.73 5.76 0.00
Price to Revenue (P/Rev)		 302.80 259.21 420.26 267.38 620.71 887.07 897.58 2,871.04 0.00 10.97 3.14
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.73
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 17.46%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.93 2.42
Enterprise Value to Revenue (EV/Rev)		 133.59 168.46 383.36 240.22 520.07 692.53 553.49 1,968.73 0.00 9.78 3.03
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.49
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.06
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.53
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.15
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 1.24 0.00 0.00 0.00 0.00 0.00 0.00 0.36
Long-Term Debt to Equity		 0.00 0.00 0.00 1.24 0.00 0.00 0.00 0.00 0.00 0.00 0.36
Financial Leverage		 -1.06 -1.08 -1.30 -1.96 -1.41 -1.11 -1.05 -1.06 -1.08 -0.83 -0.17
Leverage Ratio		 1.12 1.14 1.41 2.66 1.69 1.16 1.11 1.11 1.15 1.30 1.93
Compound Leverage Factor		 1.08 1.13 1.41 2.66 1.73 1.16 1.11 1.10 1.09 1.15 1.94
Debt to Total Capital		 0.00% 0.00% 0.00% 55.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26.30%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 55.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26.30%
Preferred Equity to Total Capital		 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 99.99% 44.61% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 73.70%
Debt to EBITDA		 0.00 0.00 0.00 -0.23 0.00 0.00 0.00 0.00 0.00 0.00 0.88
Net Debt to EBITDA		 0.00 0.00 0.00 0.44 0.00 0.00 0.00 0.00 0.00 0.00 -0.19
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.23 0.00 0.00 0.00 0.00 0.00 0.00 0.88
Debt to NOPAT		 0.00 0.00 0.00 -0.33 0.00 0.00 0.00 0.00 0.00 0.00 0.89
Net Debt to NOPAT		 0.00 0.00 0.00 0.62 0.00 0.00 0.00 0.00 0.00 0.00 -0.19
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.33 0.00 0.00 0.00 0.00 0.00 0.00 0.89
Altman Z-Score		 8.27 -1.85 -10.06 -12.34 7.43 18.12 11.40 9.34 3.17 4.94 2.27
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.11 5.34 2.12 2.40 5.04 11.58 12.44 9.44 6.97 3.39 2.11
Quick Ratio		 11.66 4.93 1.92 2.27 4.86 11.14 12.26 9.32 6.67 3.05 1.83
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -16 -21 -17 -17 -22 -20 -20 -32 -55 -178
Operating Cash Flow to CapEx		 -81,101.24% -37,915.97% -18,808.84% -48,474.35% -41,158.36% -19,502.87% -1,484.23% -11,103.54% -11,735.25% -43,735.12% 7,745.40%
Free Cash Flow to Firm to Interest Expense		 -2,728.80 -12,476.03 -3,667.41 -9,093.13 -21.05 -650.09 -1,255.85 -768.62 -937.74 -1,499.31 -63.83
Operating Cash Flow to Interest Expense		 -3,160.17 -16,983.52 -5,087.59 -12,653.80 -19.11 -661.16 -1,326.93 -918.60 -1,119.94 -1,390.32 62.92
Operating Cash Flow Less CapEx to Interest Expense		 -3,164.06 -17,028.31 -5,114.64 -12,679.90 -19.16 -664.55 -1,416.33 -926.88 -1,129.48 -1,393.50 62.11
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.02 0.03 0.01 0.01 0.00 0.00 0.00 0.43 0.63
Accounts Receivable Turnover		 1.06 1.37 8.65 11.45 51.79 141.06 7.84 0.00 0.00 0.00 2.67
Inventory Turnover		 0.00 1.35 0.30 0.78 0.97 0.85 2.03 0.00 0.00 0.66 1.18
Fixed Asset Turnover		 5.30 4.17 2.57 2.48 2.00 2.05 0.24 0.04 0.00 23.54 76.49
Accounts Payable Turnover		 0.00 0.22 0.07 0.18 0.21 0.19 0.09 0.00 0.00 1.06 4.60
Days Sales Outstanding (DSO)		 343.89 266.93 42.21 31.87 7.05 2.59 46.57 0.00 0.00 0.00 136.57
Days Inventory Outstanding (DIO)		 0.00 270.41 1,207.94 470.39 375.03 429.45 179.60 0.00 0.00 555.18 308.31
Days Payable Outstanding (DPO)		 0.00 1,669.69 5,482.44 2,022.51 1,766.77 1,917.59 4,089.77 215,622.77 0.00 343.19 79.35
Cash Conversion Cycle (CCC)		 343.89 -1,132.35 -4,232.30 -1,520.25 -1,384.69 -1,485.55 -3,863.60 -215,622.77 0.00 211.99 365.53
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.55 -2.52 -4.96 -6.74 -4.86 -2.32 -2.90 -3.96 -6.07 33 374
Invested Capital Turnover		 -0.19 -0.11 -0.09 -0.07 -0.05 -0.07 -0.07 -0.02 0.00 3.24 1.47
Increase / (Decrease) in Invested Capital		 -0.84 -0.98 -2.44 -1.77 1.87 2.55 -0.58 -1.06 -2.11 39 341
Enterprise Value (EV)		 28 38 126 103 147 166 106 129 115 425 902
Market Capitalization		 64 58 138 115 176 212 171 188 191 477 934
Book Value per Share		 $0.96 $0.44 $0.11 $0.05 $0.92 $1.38 $1.65 $1.33 $1.28 $1.44 $5.63
Tangible Book Value per Share		 $0.96 $0.44 $0.11 $0.05 $0.92 $1.38 $1.65 $1.33 $1.28 $1.41 ($0.05)
Total Capital		 34 18 7.19 11 24 44 63 55 70 85 550
Total Debt		 0.00 0.00 0.00 6.13 0.00 0.00 0.00 0.00 0.00 0.00 145
Total Long-Term Debt		 0.00 0.00 0.00 6.13 0.00 0.00 0.00 0.00 0.00 0.00 145
Net Debt		 -36 -20 -12 -12 -29 -47 -66 -59 -76 -52 -32
Capital Expenditures (CapEx)		 0.02 0.06 0.15 0.05 0.04 0.11 1.43 0.22 0.33 0.12 2.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.56 -2.60 -5.15 -6.90 -4.99 -2.52 -4.47 -5.68 -8.06 29 44
Debt-free Net Working Capital (DFNWC)		 34 18 7.01 11 24 44 61 53 68 81 193
Net Working Capital (NWC)		 34 18 7.01 11 24 44 61 53 68 81 193
Net Nonoperating Expense (NNE)		 6.53 7.31 9.96 8.02 1.73 2.97 7.60 8.26 12 2.28 0.14
Net Nonoperating Obligations (NNO)		 -36 -20 -12 -12 -29 -47 -66 -59 -76 -52 -32
Total Depreciation and Amortization (D&A)		 0.02 0.03 0.04 0.07 0.39 0.16 0.18 0.21 0.21 0.46 15
Debt-free, Cash-free Net Working Capital to Revenue		 -742.33% -1,158.89% -1,563.31% -1,604.59% -1,760.62% -1,053.49% -2,343.31% -8,678.15% 0.00% 66.82% 14.86%
Debt-free Net Working Capital to Revenue		 16,179.27% 7,915.86% 2,127.69% 2,535.81% 8,303.90% 18,400.87% 32,012.69% 81,397.21% 0.00% 185.72% 64.73%
Net Working Capital to Revenue		 16,179.27% 7,915.86% 2,127.69% 2,535.81% 8,303.90% 18,400.87% 32,012.69% 81,397.21% 0.00% 185.72% 64.73%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.90) ($3.25) ($3.00) ($0.30) ($1.80) ($0.77) ($0.75) ($0.74) ($0.91) ($0.30) $2.25
Adjusted Weighted Average Basic Shares Outstanding		 7.22M 8.14M 16.30M 119.01M 26.13M 38.02M 38.73M 40.27M 50.90M 58.87M 72.03M
Adjusted Diluted Earnings per Share		 ($2.90) ($3.25) ($3.00) ($0.30) ($1.80) ($0.77) ($0.75) $0.00 $0.00 ($0.30) $2.04
Adjusted Weighted Average Diluted Shares Outstanding		 7.22M 8.14M 16.30M 119.01M 26.13M 38.02M 38.73M 44.50M 54.98M 58.87M 80.31M
Adjusted Basic & Diluted Earnings per Share		 ($2.90) ($3.25) ($3.00) ($0.30) ($1.80) ($0.77) ($0.75) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 6.27M 7.59M 11.03M 89.08M 24.15M 28.56M 37.67M 44.50M 54.98M 0.00 79.05M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -17 -23 -19 -15 -19 -21 -21 -34 -16 105
Normalized NOPAT Margin		 -5,547.89% -7,734.16% -6,998.17% -4,375.31% -5,191.41% -7,964.91% -10,792.26% -32,773.94% 0.00% -36.00% 35.29%
Pre Tax Income Margin		 -8,352.02% -10,996.46% -10,049.50% -6,242.40% -7,587.87% -11,368.54% -15,429.47% -46,305.23% 0.00% -44.45% 50.37%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4,602.41 -18,893.28 -5,908.67 -14,342.97 -26.70 -818.55 -1,847.76 -1,153.57 -1,428.35 -600.66 53.54
NOPAT to Interest Expense		 -2,940.91 -13,220.93 -4,101.60 -10,040.01 -18.67 -573.48 -1,292.50 -808.48 -999.26 -429.87 58.66
EBIT Less CapEx to Interest Expense		 -4,606.31 -18,938.07 -5,935.72 -14,369.07 -26.75 -821.94 -1,937.16 -1,161.84 -1,437.90 -603.84 52.73
NOPAT Less CapEx to Interest Expense		 -2,944.81 -13,265.73 -4,128.65 -10,066.11 -18.72 -576.87 -1,381.90 -816.75 -1,008.80 -433.05 57.85
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -1.38% 0.00% 0.00% 0.00% 0.00% 0.00% 3.51%

Quarterly Metrics And Ratios for CorMedix

This table displays calculated financial ratios and metrics derived from CorMedix's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 54,812,042.00 54,812,042.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 54,812,042.00 54,812,042.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 0.26 0.70
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,829.40% 778.54% 279.28% 226.05%
EBITDA Growth		 -51.68% -86.34% -51.99% -29.08% 69.31% 187.33% 221.84% 234.32% 1,836.63% 422.57% 218.12%
EBIT Growth		 -51.28% -85.77% -51.83% -29.48% 68.36% 185.94% 220.22% 231.92% 1,664.87% 342.59% 169.55%
NOPAT Growth		 -50.35% -86.77% -51.62% -29.62% 68.59% 217.94% 272.11% 277.79% 4,707.41% 13.52% 119.43%
Net Income Growth		 -42.18% -79.73% -36.90% -25.53% 71.50% 191.26% 242.71% 240.11% 4,009.63% 4.13% 86.98%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 70.59% 0.00% 220.00% 212.00% 2,620.00% -20.00% 43.33%
Operating Cash Flow Growth		 -45.07% -74.59% -66.54% -63.78% -56.94% 47.75% 214.02% 313.62% 326.06% 1,782.34% 114.73%
Free Cash Flow Firm Growth		 -19.89% -83.95% -72.13% -83.70% -174.78% -193.47% -30.28% 27.07% -909.86% -1,154.30% -795.46%
Invested Capital Growth		 -37.01% -53.29% 87.29% 115.93% 517.02% 641.51% 15,531.26% 6,253.91% 2,279.74% 1,036.87% 536.32%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 777.11% 168.07% 27.26% 1.68% 153.28% 17.61% 7.65%
EBITDA Q/Q Growth		 11.24% -49.49% -6.64% 8.78% 78.89% 525.33% 48.78% -2.75% 182.19% 23.29% -3.58%
EBIT Q/Q Growth		 11.18% -49.26% -6.64% 8.41% 78.30% 505.46% 49.19% -2.79% 166.11% 10.41% -3.01%
NOPAT Q/Q Growth		 11.33% -49.69% -6.61% 8.40% 78.52% 662.16% 55.58% -5.38% 456.76% -86.15% 200.70%
Net Income Q/Q Growth		 13.57% -51.41% 1.95% 2.18% 80.38% 584.89% 53.32% -3.95% 447.52% -87.09% 175.33%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6.67% 350.00% -84.13% 115.00%
Operating Cash Flow Q/Q Growth		 -1.46% -23.55% -61.09% 18.89% 2.78% 58.87% 451.53% 51.96% 2.88% 206.13% -55.13%
Free Cash Flow Firm Q/Q Growth		 15.30% -36.02% -50.74% -5.78% -26.69% -45.28% 33.08% 40.78% -1,654.24% -80.44% 52.22%
Invested Capital Q/Q Growth		 -2.42% -101.22% 96.02% 294.22% 2,580.55% 161.29% 13.44% -20.03% 903.95% 24.83% -36.51%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 22.68% 94.01% 97.80% 95.91% 95.31% 92.48% 90.65% 82.50%
EBITDA Margin		 0.00% 0.00% 0.00% -1,162.91% -27.98% 44.40% 51.91% 49.65% 55.32% 57.99% 51.94%
Operating Margin		 0.00% 0.00% 0.00% -1,171.47% -28.70% 42.12% 51.50% 49.18% 51.02% 49.95% 49.96%
EBIT Margin		 0.00% 0.00% 0.00% -1,171.59% -28.99% 43.84% 51.40% 49.14% 51.63% 48.47% 43.67%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -1,083.48% -24.24% 43.84% 52.82% 49.90% 107.87% 11.84% 30.29%
Tax Burden Percent		 100.00% 100.00% 91.21% 100.00% 100.00% 100.00% 100.00% 97.44% 206.49% 24.84% 69.37%
Interest Burden Percent		 92.83% 94.17% 94.93% 92.48% 83.62% 100.00% 102.77% 104.21% 101.18% 98.38% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.56% -106.49% 75.16% 30.63%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -53.62% 136.68% 229.55% 384.50% 142.31% 18.18% 97.51%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -52.90% 135.86% 228.79% 383.83% 138.11% 19.78% 101.52%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 49.34% -112.34% -179.78% -340.27% -38.59% -3.37% -51.03%
Return on Equity (ROE)		 -57.05% -74.02% -89.76% -111.55% -4.28% 24.34% 49.77% 44.23% 103.72% 14.81% 46.48%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -9,401.45% -407.60% -166.09% -61.83% 128.63% -82.67% -87.37% -7.62%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -26.67% -4.38% 18.97% 39.00% 38.47% 26.26% 30.55% 34.94%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -24.66% -3.66% 18.97% 40.08% 39.07% 54.86% 7.47% 24.24%
Return on Common Equity (ROCE)		 -57.05% -74.02% -89.76% -111.55% -4.28% 24.34% 49.77% 44.23% 103.72% 14.81% 46.48%
Return on Equity Simple (ROE_SIMPLE)		 -47.83% 0.00% -86.60% -115.01% -78.60% 0.00% 14.95% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.33 -11 -12 -11 -2.30 13 20 19 106 15 44
NOPAT Margin		 0.00% 0.00% 0.00% -820.03% -20.09% 42.12% 51.50% 47.92% 105.34% 12.41% 34.65%
Net Nonoperating Expense Percent (NNEP)		 -3.34% -5.60% -4.86% -7.04% -0.72% 0.83% 0.76% 0.66% 4.20% -1.59% -4.01%
Return On Investment Capital (ROIC_SIMPLE)		 - -15.64% - - - 15.28% 17.52% 8.63% 28.05% 2.67% 10.10%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 39.03% 5.99% 3.83% 4.09% 4.69% 7.52% 9.35% 17.50%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 578.76% 57.44% 2.51% 24.80% 23.92% 25.29% 19.91% 17.05%
R&D to Revenue		 0.00% 0.00% 0.00% 49.84% 6.35% 5.62% 8.17% 6.15% 5.06% 7.27% 5.66%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 1,194.16% 122.70% 55.68% 44.42% 46.13% 41.47% 40.70% 32.54%
Earnings before Interest and Taxes (EBIT)		 -10 -16 -17 -15 -3.32 13 20 20 52 57 56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -10 -16 -17 -15 -3.21 14 20 20 56 69 66
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.51 2.73 4.02 5.24 8.10 5.63 3.70 4.02 2.68 2.30 1.44
Price to Tangible Book Value (P/TBV)		 2.51 2.73 4.16 5.47 8.37 5.76 3.76 4.05 0.00 0.00 16.50
Price to Revenue (P/Rev)		 7,044.87 0.00 0.00 185.19 37.24 10.97 5.15 7.29 4.76 3.14 1.63
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 24.73 17.32 6.17 5.73 3.49
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.04% 5.77% 16.21% 17.46% 28.67%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 418.06 34.12 12.93 9.32 23.32 3.10 2.42 1.81
Enterprise Value to Revenue (EV/Rev)		 4,142.11 0.00 0.00 150.18 33.63 9.78 4.21 5.72 4.40 3.03 1.11
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 22.36 13.92 8.53 5.49 2.20
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 23.26 14.11 8.88 6.06 2.33
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 23.99 14.24 5.88 5.53 2.26
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 22.82 12.38 5.15 2.17
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 35.70 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.36 0.00
Long-Term Debt to Equity		 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.36 0.00
Financial Leverage		 -1.04 -1.08 -1.02 -1.03 -0.93 -0.83 -0.79 -0.89 -0.28 -0.17 -0.50
Leverage Ratio		 1.10 1.15 1.14 1.21 1.19 1.30 1.26 1.16 1.91 1.93 1.75
Compound Leverage Factor		 1.02 1.08 1.08 1.11 1.00 1.30 1.29 1.21 1.94 1.90 1.75
Debt to Total Capital		 0.66% 0.00% 0.81% 0.00% 0.00% 0.00% 0.00% 0.00% 1.01% 26.30% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.22% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.66% 0.00% 0.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.79% 26.30% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.34% 100.00% 99.18% 100.00% 100.00% 100.00% 100.00% 100.00% 98.99% 73.70% 100.00%
Debt to EBITDA		 -0.01 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.04 0.88 0.00
Net Debt to EBITDA		 2.08 0.00 1.07 0.00 0.00 0.00 0.00 0.00 -0.69 -0.19 0.00
Long-Term Debt to EBITDA		 -0.01 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.03 0.88 0.00
Debt to NOPAT		 -0.02 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.02 0.89 0.00
Net Debt to NOPAT		 2.96 0.00 1.52 0.00 0.00 0.00 0.00 0.00 -0.47 -0.19 0.00
Long-Term Debt to NOPAT		 -0.02 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.02 0.89 0.00
Altman Z-Score		 11.25 4.51 7.19 4.10 9.61 5.92 6.24 16.74 1.95 1.90 1.84
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 11.61 6.97 6.65 4.79 3.96 3.39 4.21 7.82 1.94 2.11 2.98
Quick Ratio		 11.29 6.67 6.14 4.12 3.43 3.05 3.84 7.37 1.60 1.83 2.59
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.51 -8.86 -13 -14 -18 -26 -17 -10 -181 -326 -156
Operating Cash Flow to CapEx		 -84,894.78% -3,631.15% -28,235.89% -40,357.34% -139,769.68% -56,890.63% 193,932.43% 125,252.93% 6,100.85% 5,491.60% 5,813.72%
Free Cash Flow to Firm to Interest Expense		 -496.63 -1,351.17 -1,357.69 -2,154.45 -1,788.21 -2,597.87 -1,738.42 -1,544.21 -190.58 -179.45 0.00
Operating Cash Flow to Interest Expense		 -663.27 -1,639.06 -1,760.07 -2,141.54 -1,364.04 -561.06 1,972.27 4,495.85 32.54 51.99 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -664.05 -1,684.20 -1,766.30 -2,146.84 -1,365.01 -562.05 1,971.25 4,492.26 32.01 51.04 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.02 0.15 0.43 0.76 0.78 0.51 0.63 0.80
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.64 2.39 2.67 3.69
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.66 0.81 0.78 0.69 1.18 2.24
Fixed Asset Turnover		 0.02 0.00 0.00 0.74 7.32 23.54 45.44 68.31 44.73 76.49 97.84
Accounts Payable Turnover		 0.00 0.00 0.38 0.43 1.08 1.06 1.67 1.16 1.12 4.60 5.80
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 64.77 152.43 136.57 98.97
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 555.18 451.02 468.00 529.74 308.31 162.98
Days Payable Outstanding (DPO)		 1,867,035.68 0.00 952.68 858.02 337.83 343.19 218.86 314.16 324.68 79.35 62.94
Cash Conversion Cycle (CCC)		 -1,867,035.68 0.00 0.00 -858.02 -337.83 211.99 232.16 218.62 357.50 365.53 199.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.02 -6.07 -0.24 0.47 13 33 37 30 299 374 237
Invested Capital Turnover		 -0.01 0.00 0.00 -1.06 2.67 3.24 4.46 8.02 1.35 1.47 2.81
Increase / (Decrease) in Invested Capital		 -0.81 -2.11 1.66 3.41 16 39 38 29 287 341 200
Enterprise Value (EV)		 123 115 175 196 429 425 347 695 928 902 429
Market Capitalization		 209 191 233 242 475 477 425 886 1,003 934 631
Book Value per Share		 $1.52 $1.28 $1.01 $0.80 $1.00 $1.44 $1.76 $3.25 $4.93 $5.63 $5.50
Tangible Book Value per Share		 $1.52 $1.28 $0.97 $0.77 $0.97 $1.41 $1.73 $3.22 ($0.44) ($0.05) $0.48
Total Capital		 84 70 58 46 59 85 115 221 378 550 437
Total Debt		 0.56 0.00 0.48 0.00 0.00 0.00 0.00 0.00 3.81 145 0.00
Total Long-Term Debt		 0.56 0.00 0.48 0.00 0.00 0.00 0.00 0.00 2.97 145 0.00
Net Debt		 -86 -76 -58 -46 -46 -52 -78 -191 -75 -32 -202
Capital Expenditures (CapEx)		 0.01 0.30 0.06 0.03 0.01 0.01 0.01 0.02 0.51 1.72 0.73
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.28 -8.06 -4.75 -3.53 8.64 29 33 26 71 44 76
Debt-free Net Working Capital (DFNWC)		 81 68 54 42 55 81 110 216 127 193 254
Net Working Capital (NWC)		 81 68 54 42 55 81 110 216 126 193 254
Net Nonoperating Expense (NNE)		 2.42 3.79 2.77 3.44 0.48 -0.53 -0.52 -0.79 -2.54 0.67 5.56
Net Nonoperating Obligations (NNO)		 -86 -76 -58 -46 -46 -52 -78 -191 -75 -32 -200
Total Depreciation and Amortization (D&A)		 0.05 0.05 0.06 0.11 0.11 0.17 0.20 0.20 3.71 11 11
Debt-free, Cash-free Net Working Capital to Revenue		 -17,776.99% 0.00% 0.00% -270.06% 67.73% 66.82% 39.94% 21.10% 33.71% 14.86% 19.74%
Debt-free Net Working Capital to Revenue		 274,026.98% 0.00% 0.00% 3,221.99% 428.40% 185.72% 133.82% 178.09% 60.16% 64.73% 65.86%
Net Working Capital to Revenue		 274,026.98% 0.00% 0.00% 3,221.99% 428.40% 185.72% 133.82% 178.09% 59.76% 64.73% 65.86%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.17) ($0.25) ($0.25) ($0.25) ($0.05) $0.25 $0.32 $0.29 $1.42 $0.22 $0.48
Adjusted Weighted Average Basic Shares Outstanding		 56.55M 50.90M 57.50M 57.62M 58.83M 58.87M 65.24M 67.93M 75.93M 72.03M 79.51M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.05) $0.00 $0.30 $0.28 $1.26 $0.20 $0.43
Adjusted Weighted Average Diluted Shares Outstanding		 54.81M 50.90M 54.96M 55.86M 58.83M 58.87M 68.98M 71.92M 86.21M 80.31M 92.99M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 54.81M 54.98M 54.96M 55.86M 60.68M 0.00 67.82M 74.65M 78.79M 79.05M 78.45M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.33 -11 -12 -11 -2.30 9.06 14 19 36 41 44
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -820.03% -20.09% 29.49% 36.05% 47.92% 35.71% 34.96% 34.65%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -1,083.48% -24.24% 43.84% 52.82% 51.21% 52.24% 47.69% 43.67%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -800.46 -2,389.80 -1,698.86 -2,334.09 -331.83 1,345.46 2,007.31 2,927.18 54.80 31.57 0.00
NOPAT to Interest Expense		 -558.77 -1,672.99 -1,188.91 -1,633.71 -229.95 1,292.70 2,011.12 2,854.54 111.81 8.08 0.00
EBIT Less CapEx to Interest Expense		 -801.25 -2,434.94 -1,705.09 -2,339.40 -332.81 1,344.47 2,006.29 2,923.59 54.27 30.63 0.00
NOPAT Less CapEx to Interest Expense		 -559.55 -1,718.13 -1,195.15 -1,639.01 -230.93 1,291.71 2,010.10 2,850.95 111.28 7.14 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.51% 9.29%

Financials Breakdown Chart

Key Financial Trends

CorMedix (NASDAQ: CRMD) shows a dramatic turnaround over the last several years, culminating in very strong profitability and cash generation in Q1 2026. Revenue has surged, margins have improved sharply, and the balance sheet now looks much larger and more liquid than it did a year ago. That said, investors should also note the company’s large deferred tax-related liabilities and the fact that cash flow can be volatile quarter to quarter because of working-capital swings and investing activity.

  • Revenue jumped to $127.4 million in Q1 2026, up from $118.4 million in Q4 2025 and far above the sub-$40 million level seen earlier in 2025.
  • Gross profit was very strong at $105.1 million, with gross margin around 82%, indicating a highly profitable revenue mix.
  • Operating income rose to $63.7 million in Q1 2026, showing the business is generating substantial profit before taxes and interest.
  • Net income reached $38.6 million in Q1 2026, compared with $14.0 million in Q4 2025 and much smaller or negative results in the prior year.
  • Cash from operations was strong at $42.4 million in Q1 2026, a big improvement from $30.9 million in Q3 2025 and $94.5 million in Q4 2025.
  • The company ended Q1 2026 with $178.1 million in cash and equivalents, plus $24.3 million in long-term investments, giving it a sizable liquidity cushion.
  • Total equity increased to $437.0 million in Q1 2026, up sharply from $374.1 million in Q3 2025 and $114.9 million in Q1 2025.
  • Quarterly cash flow has been supported by meaningful non-cash items and working-capital movements, so investors should watch whether operating cash generation remains consistent.
  • The company has no short-term debt on the latest balance sheet and only minimal debt-related outflows in recent quarters, which reduces near-term balance sheet pressure.
  • Q1 2026 included a large $11.1 million repurchase of common equity, which reduced cash and may not be ideal if investors prefer capital preservation.
  • The balance sheet still carries substantial liabilities, including $144.9 million in noncurrent deferred and payable income tax liabilities and $102.4 million in other noncurrent operating liabilities.
  • Revenue and earnings growth have been uneven historically, with several 2022–2024 quarters showing losses and weak or zero revenue before the recent surge.

Bottom line: CorMedix’s recent financials look much stronger than in prior years, with rapid revenue growth, high margins, and solid cash generation. The key question for investors is whether this improved profitability is sustainable and whether cash flow can stay strong without relying on big working-capital swings or non-core balance sheet items.

06/26/26 09:36 PM ETAI Generated. May Contain Errors.

CorMedix Financials - Frequently Asked Questions

According to the most recent income statement we have on file, CorMedix's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

CorMedix's net income appears to be on a downward trend, with a most recent value of $163.06 million in 2025, falling from -$18.19 million in 2015. The previous period was -$17.93 million in 2024. View CorMedix's forecast to see where analysts expect CorMedix to go next.

CorMedix's total operating income in 2025 was $150.14 million, based on the following breakdown:
  • Total Gross Profit: $275.75 million
  • Total Operating Expenses: $125.61 million

Over the last 10 years, CorMedix's total revenue changed from $210.13 thousand in 2015 to $297.84 million in 2025, a change of 141,639.4%.

CorMedix's total liabilities were at $420.84 million at the end of 2025, a 1,130.9% increase from 2024, and a 13,518.2% increase since 2015.

In the past 10 years, CorMedix's cash and equivalents has ranged from $8.06 million in 2016 to $144.84 million in 2025, and is currently $144.84 million as of their latest financial filing in 2025.

Over the last 10 years, CorMedix's book value per share changed from 0.96 in 2015 to 5.63 in 2025, a change of 485.3%.


Related Companies

Financial statements for NASDAQ:CRMD last updated on 6/11/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Problems at SpaceX: time to get out?
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Solar is dead. Here’s what replaces it.
Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...
Behind the Markets | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel